MediPharm Labs has completed its second shipment of medical cannabis extracts to Australia and it was even more abundant than the first.
According to Medipharm Labs, the shipment packed 137 percent more product than the company’s first export into Australia in June.
“We are pleased to have completed our second set of shipments of medical cannabis concentrate into Australia in the third quarter as we look to participate in addressing the growing Australian medical patient demand,” said Medipharm Labs CEO, Pat McCutcheon.
Austalia legalized medical cannabis in 2016. In the two years since then, more than 1,000 patients have received approval for treatment. While the number seems low, Canada had only 150 patients in its first year. Today there are 300,000 plus medicinal cannabis users in Canada.
In addition to medicinal cannabis, lawmakers in the Australian Capital Territory passed a bill on September 25 to legalize cannabis for personal use. The new bill will take effect in January 2020.
“As international demand for purified cannabis concentrates continues to grow, we have focused on expanding our global supply chain and our international presence,” said McCutcheon. Medipharm Labs also recently signed a supply agreement for the German medical market.
About Medipharm Labs
Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-like cannabis concentrates and advanced derivative products. The company’s concentrates can be used as a base ingredient for any cannabis-infused products including topicals, edibles, and cannabinoid-based medicines.
Medipharm Labs received its cannabis oil production license from Health Canada in March 2018.
In addition to it’s Barrie, Ontario facility, the company has launched cannabis extraction services in Australia. Pending approval from the Office of Drug Control Australia, the company will be producing cannabis oil down under by 2020.